Compare Incyte Corporation (INCY) vs Ralph Lauren Corp (RL) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Incyte Corporation vs Ralph Lauren Corp — how do they compare? Incyte Corporation trades at $118.9 (market cap $23.11B), while Ralph Lauren Corp trades at $384.86 (market cap $22.41B). The key difference: Incyte Corporation and Ralph Lauren Corp are close in size by market cap, and Ralph Lauren Corp pays a 0.99% dividend while Incyte Corporation pays none. Which is the better fit depends on your goals.
| INCY | RL | |
|---|---|---|
Market Cap | $23.11B | $22.41B |
Sector | Health | Consumer Cyclical |
52-Week High | $118.52 | $414.25 |
52-Week Low | $67.38 | $283.34 |
Enterprise Value | $19.13B | $23.35B |
Dividend Yield | — | 0.99% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
INCY trades at $115.66, down 1.36% on the day, with a bullish technical signal from moving averages and strong fundamental performance including a 25.02% net income margin for 2025. Recent positive news includes regulatory approvals for Opzelura in Europe and the acquisition of Vega Therapeutics, expanding its hematology portfolio. Revenue grew to $5.14 billion in 2025, with earnings beating expectations in two of the last three quarters.
The outlook remains positive given robust profitability, pipeline advancements, and a majority analyst buy rating, though risks include competitive pressures and reliance on key drug performance. The stock's current price is slightly above the consensus target of $112.78, suggesting near-term consolidation potential amid longer-term growth catalysts.
Ralph Lauren (RL) trades at $376.55, down 1.03% on the day, with a neutral technical signal and key support at $370. The company demonstrates strong fundamentals, with revenue growing to $7.08B in 2025 and net income of $742.9M, supported by a 69.87% gross margin and consistent earnings beats. Analyst consensus is bullish with a $445.71 price target, and recent news highlights brand strength and digital expansion.
The outlook for RL is positive, driven by earnings momentum and strategic initiatives, though premium valuation and market volatility present risks. Upside potential exists if the company maintains its growth trajectory and meets Q2 2026 EPS expectations of $4.26.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Incyte Corporation
Incyte focuses on the discovery and development of small-molecule drugs. The firm's lead drug, Jakafi, treats two types of rare blood cancer and graft versus host disease and is partnered with Novartis. Incyte's other marketed drugs include rheumatoid arthritis treatment Olumiant (licensed to Lilly), and oncology drugs Iclusig (chronic myeloid leukemia), Pemazyre (cholangiocarcinoma), Tabrecta (lung cancer), and Monjuvi (diffuse large B-cell lymphoma). The firm's first dermatology product, Opzelura, was approved in 2021 for atopic dermatitis. Incyte's pipeline includes a broad array of oncology and dermatology programs.
Read more on INCY →About Ralph Lauren Corp
Founded by designer Ralph Lauren in 1967, Ralph Lauren Corp. designs, markets, and distributes lifestyle products in North America, Europe, and Asia. Its products include apparel, footwear, eyewear, jewelry, leather goods, home products, and fragrances. The company's brands include Ralph Lauren Collection, Polo Ralph Lauren, Lauren Ralph Lauren, and Double RL. Distribution channels for Ralph Lauren include wholesale (including department stores and specialty stores), retail (including company-owned retail stores and e-commerce), and licensing.
Read more on RL →
